about
Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo.Haemophilia therapies.Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicityInfluence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A miceAchievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Factor VIII inhibitors in hemophilia A: rationale and latest evidenceProduction of recombinant coagulation factors: Are humans the best host cells?Teaching tolerance: New approaches to enzyme replacement therapy for Pompe diseaseAnimal models of FVIIa gene expression: their role in the future development of haemophilia treatmentBaboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in vivo in NOD/SCIDγc-/- mice.Managing haemophilia for life: 4th Haemophilia Global Summit.Factor VIII intron-1 inversion: frequency and inhibitor prevalence.Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol.Inhibitor screening in non-severe haemophilia patients; a major challenge.Prevalence of the factor 8 gene intron 1 inversion in Chinese haemophiliacs and its application to carrier detection and prenatal diagnosis in haemophilia A families.Prenatal diagnosis of haemophilia A by using intron 1 inversion detection.Factor VIII haplotypes of Japanese population show similarity to those of Caucasian populations.
P2860
Q31098999-135585B4-F436-4734-ABB3-21D964D9AF91Q35782984-043E28B9-C856-47BF-9052-EABDAD1357CFQ36810282-C4F6BF64-1785-4A1D-87A7-D14FB96DADD5Q36950922-5DE2CC88-849C-42FD-BCAD-FD92FF18CCB3Q36951646-0DCF9821-070B-4A53-87E0-AA7BFD673362Q37185097-C28D74A3-0531-4B47-8737-6FFA83F9F361Q38101041-20BAFC57-7179-44C3-8590-146B1BCEB7F0Q39170433-A4730D99-1C4B-4C16-B181-2F67F6FBB352Q39531026-2906B146-C891-4C13-8936-C0DC4A80C15EQ39898071-9CC165A2-2DE1-4BAC-9811-0247A3B1B125Q40560385-FC9AD4C7-8F14-446F-9E30-4C065512A54AQ44122887-E57C4C13-8DFC-41D7-9F08-EB7773214B93Q45858208-B905E03E-1642-416A-BDCC-68D30CAB6434Q45863589-4D10F0A1-B59D-463C-9FFB-4093F541EDB4Q45864597-96C3E8B7-1C4B-47A4-92D9-9CFFAFCFF8BAQ45865359-237D7213-1E9E-4A37-B321-6CEE78EE7365Q45872384-79D8CE4B-68BC-4010-A2CE-7BAFFE70DAA5Q45875937-643B1330-25E6-4716-945D-78C901D009CE
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Inhibitors in haemophilia: pathophysiology.
@ast
Inhibitors in haemophilia: pathophysiology.
@en
type
label
Inhibitors in haemophilia: pathophysiology.
@ast
Inhibitors in haemophilia: pathophysiology.
@en
prefLabel
Inhibitors in haemophilia: pathophysiology.
@ast
Inhibitors in haemophilia: pathophysiology.
@en
P2093
P2860
P1433
P1476
Inhibitors in haemophilia: pathophysiology.
@en
P2093
J Oldenburg
J-M R Saint-Remy
S Lacroix-Desmazes
P2860
P304
P356
10.1111/J.1365-2516.2004.01009.X
P478
10 Suppl 4
P577
2004-10-01T00:00:00Z